|Description||Idebenone is a synthetic variant of coenzyme Q10 (CoQ10), which initially developed for the treatment of Alzheimer’s disease and other cognitive defects. Target: Others Idebenone is a synthetic variant of coenzyme Q10 (CoQ10), which initially developed for the treatment of Alzheimer’s disease and other cognitive defects. Idebenone was generally well tolerated with similar numbers of adverse events in each group. One child receiving high-dose idebenone developed neutropenia after 6 months, which resolved after discontinuation of treatment. 8OH2′dG concentrations were not increased, and did not significantly change with idebenone treatment . The 2-year efficacy and safety of idebenone were studied in a prospective, randomized, double-blind multicentre study in 3 parallel groups of patients with dementia of the Alzheimer type (DAT) of mild to moderate degree. A total of 450 patients were randomized to either placebo for 12 months, followed by idebenone 90 mg tid for another 12 months (n = 153) or idebenone 90 mg tid for 24 months (n = 148) or 120 mg tid for 24 months (n = 149). idebenone showed statistically significant dose-dependent improvement in the primary efficacy variable ADAS-Total and in all the secondary efficacy variables .|
|Preparing Stock Solutions||
Please refer to the solubility information to select the appropriate solvent.
|Shipping||Room temperature in continental US; may vary elsewhere|
|Solvent & Solubility||DMSO
Idebenone is dissolved in DMSO, then diluted with physiological saline. The final concentration of DMSO is 0.1%.
* “<1 mg/mL” means slightly soluble or insoluble. “≥” means soluble, but saturation unknown.